Enveric Biosciences, Inc. (ENVB) 株式分析

企業概要

Enveric Biosciences, Inc. (ENVB) is a biotechnology entity focused on the development of small-molecule therapeutics designed to treat anxiety, depression, and addiction disorders. The company operates within the healthcare sector and specifically functions in the biotechnology industry, where it leverages research and development to advance product candidates such as EB-002, an active metabolite of psilocybin currently in preclinical development. As of the latest available data, the company maintains a market capitalization of $3.85M, has a reported annual revenue of N/A, and employs a workforce of 5 individuals. These valuation figures indicate that the company operates at a very small scale with limited current commercial output, characteristic of early-stage biotechnology firms that are investing heavily in research before generating significant sales revenue. The minimal employee count further suggests a lean organizational structure typical of entities prioritizing intellectual property development over large-scale manufacturing operations at this stage.

財務健全性

The company's financial statements report a Net Income (TTM) of $-12,131,472, an EBITDA of $-8,573,590, and a Revenue (TTM) of N/A. The substantial gap between the reported net income and EBITDA reveals a significant cost structure driven by non-operating expenses or one-time charges that heavily impact the bottom line relative to operating earnings. Furthermore, the Free Cash Flow stands at $-4,792,909, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility for external expansion without additional capital raises. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that reflects the company's status as a pre-revenue entity where traditional profitability measures are not yet applicable due to the absence of sales. On the balance sheet, the company holds $4.68M in cash against $0 in debt, creating a highly conservative capital position with no leverage to speak of. This liquidity buffer of $4.68M provides a runway for operations, while the debt-to-equity ratio is effectively N/A given the absence of debt. The Current Ratio is 5.38, which signifies robust short-term liquidity, ensuring the company can comfortably meet its obligations as they come due. Finally, the Return on Equity is -304.0% and the Return on Assets is -134.1%, metrics that reveal that management is currently deploying capital in a manner that generates negative returns, a common reality for developmental-stage biotech firms prior to product approval.

バリュエーション評価

The valuation metrics for Enveric Biosciences show a Trailing P/E (TTM) of N/A and a Forward P/E of -1.45, implying that the market is valuing the company based on future expectations of profitability rather than current earnings, though the negative forward P/E suggests anticipated losses or non-earnings-based pricing. The Price to Book ratio is 0.52, indicating that the company's market capitalization trades at less than its book value, which often signals a deep discount or a market's skepticism regarding the realization of the company's intangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is 0.10, suggesting that traditional sales-based valuation is not applicable due to lack of revenue, while the EV/EBITDA metric reflects a very low multiple driven by the high negative earnings. Regarding price volatility, the 52-week high is $17.84 and the 52-week low is $1.75. Without the current specific stock price listed in the provided facts to calculate the exact percentage, the stock's position relative to this wide range demonstrates extreme price fluctuation typical of small-cap biotechnology shares. The Beta is 0.33, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it is less sensitive to general market movements and behaves more as a defensive or idiosyncratic asset.

Growth & Income

The company reports a Revenue Growth (YoY) of N/A and an Earnings Growth (YoY) of N/A, meaning that historical growth rates cannot be calculated due to the absence of comparable prior year data in the provided facts. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue based on the available information, as the company has not yet established a track record of commercial sales. As the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which means the company reinvests all available resources, including its cash reserves, into research and development rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms in the preclinical phase, where capital is directed toward advancing product candidates like EB-002 through clinical trials. Overall, the growth and income profile of Enveric Biosciences is characterized by a complete absence of commercial growth metrics and dividend income, reflecting a capital-intensive business model reliant on external funding to sustain operations until product commercialization occurs.